Martin Petkovich

USPTO Granted Patents = 16 (Patent Applications = 1)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 88(Granted Patents)

Location History:

Strasbourg, FR (1994)
67085 Strasbourg, FR (1995)
Kingston, CA (1999 - 2023)

Company Filing History:

Queen's University at Kingston

Wisconsin Alumni Research Foundation

patents

5. 1 out of 5

Proventiv Therapeutics, LLC

patents

6. 1 out of 3,681

Bristol-myers Squibb Compnay

patents

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297173 - Compounds and methods for inhibiting CYP26 enzymes (2025-05-13),

2. 11795148 - Compounds and methods for inhibiting CYP26 enzymes (2023-10-24),

3. 11364220 - Compounds and methods for inhibiting CPY26 enzymes (2022-06-21),

4. 11358933 - Compounds and methods for inhibiting CYP26 enzymes (2022-06-14),

5. 10874634 - Compounds and methods for inhibiting CYP26 enzymes (2020-12-29),

6. 8877198 - Methods of reducing phosphate absorption (2014-11-04),

7. 8802094 - Method of reducing phosphate absorption by administering orally an IgY anti-intestinal sodium phosphate cotransporter type 2B antibody (2014-08-12),

8. 8329677 - Method of treating and preventing secondary hyperparathyroidism (2012-12-11),

9. 7579329 - P450RAI-2 (P450 cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof (2009-08-25),

10. 7537919 - Cytochrome P450RAI-2 and related proteins (2009-05-26),

11. 7335756 - Retinoic acid metabolizing cytochrome P450 (2008-02-26),

12. 7115558 - P450RAI-2(P450 Cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof (2006-10-03),

13. 5922596 - Promoter of the retinoic acid receptor gene for directing gene expression (1999-07-13),

14. 5468617 - Steroid/thyroid hormone receptor-related gene, which is inappropriately (1995-11-21),

15. 5376530 - Steroid/thyroid hormone receptor-related gene, which is inappropriately (1994-12-27),

Title: The Innovative Contributions of Martin Petkovich

Introduction

Martin Petkovich is a distinguished inventor based in Kingston, Canada. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit CYP26 enzymes. With a total of 16 patents to his name, Petkovich's work has the potential to impact the treatment of various diseases responsive to retinoids.

Latest Patents

Among his latest patents are innovative compounds and methods for inhibiting CYP26 enzymes. These compounds serve as inhibitors of retinoic acid inducible P450 (CYP26) enzymes. They exhibit retinoid activity, resist CYP26-mediated catabolism, and act specifically as inhibitors of CYP26B1. The applications of these compounds are particularly relevant in treating diseases that respond positively to retinoids.

Career Highlights

Throughout his career, Martin Petkovich has worked with notable organizations such as Cytochroma Inc. and Queen's University at Kingston. His research and development efforts have led to advancements in understanding the role of CYP26 enzymes in various biological processes.

Collaborations

Petkovich has collaborated with esteemed colleagues, including Donald Andrew Cameron and Pierre H Chambon. These partnerships have further enriched his research and contributed to the scientific community's understanding of retinoid biology.

Conclusion

Martin Petkovich's innovative work in the field of biochemistry, particularly regarding CYP26 enzymes, showcases his dedication to advancing medical science. His numerous patents reflect a commitment to developing effective treatments for diseases influenced by retinoids.

This text is generated by artificial intelligence and may not be accurate.